Advanced search
Publication Cover
Cytotherapy Volume 11, 2009 - Issue 1
Journal homepage
36
Views
1
CrossRef citations to date
0
Altmetric
Original papers

A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus

Michael Y. Shapira Department of Bone Marrow Transplantation and Cancer ImmunotherapyCorrespondence[email protected]
, MD,
Igor B. Resnick Department of Bone Marrow Transplantation and Cancer Immunotherapy
,
Liliane Dray Department of Bone Marrow Transplantation and Cancer Immunotherapy
,
Memet Aker Pediatric Hemato-Oncology, Hadassah–Hebrew University Medical Center, Jerusalem, Israel
,
Polina Stepensky Pediatric Hemato-Oncology, Hadassah–Hebrew University Medical Center, Jerusalem, Israel
,
Sharon Elad Department of Bone Marrow Transplantation and Cancer Immunotherapy
,
Benjamin Gesundeheidt Department of Bone Marrow Transplantation and Cancer Immunotherapy
,
Simcha Samuel Department of Bone Marrow Transplantation and Cancer Immunotherapy
&
Reuven Or Department of Bone Marrow Transplantation and Cancer Immunotherapy
 show all
Pages 61-67 | Published online: 30 Jun 2009

References

  • Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant. 2005; 36: 1097–101
  • Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007; 18: 13–18
  • Shapira MY Abdul-Hai A Resnick IB Bitan M Tsirigotis P Aker M , et al. Alefacept treatment for chronic extensive graft-versus-host disease. Bone Marrow Transplant. 2008, 13 Oct (Epub ahead of print).
  • Abdul-Hai A, Resnick IB, Bitan M, Tsirigotis PD, Aker M, Gesundheit B, et al. The effect of alefacept treatment on lymphoid subpopulations in patients with chronic extensive graft-versus-host disease. Bone Marrow Transplant. 2007; 39(Suppl 1)S117–18
  • Devergie A. Graft versus host disease. Apperley J, Carreras E, Gluckman E, Gratwol A, Masszi T. “Haemapoietic Stem Cell Transplantation EBMT Handbook. ESH-EBMT, France 2004; 173
  • Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997; 97: 855–64
  • Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant. 1996; 17: 273–5
  • Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M, et al. Variable number of tandem repeat (VNTR) markets for human gene mapping. Science. 1987; 235: 1616–22
  • Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007; 25: 139–170
  • Cohen JL, Boyer O. The role of CD4(+)CD25(hi) regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol. 2006; 18: 580–585
  • Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002; 29: 415–26
  • Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg. 2004; 8: 14–19
  • Bashir SJ, Maibach HI. Alefacept (Biogen). Curr Opin Investig Drugs. 2001; 2: 631–4
  • Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur J Immunol. 2003; 33: 666–75
  • Duran-Struuck R, Reddy P. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2008; 85: 303–8
  • Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007; 7: 340–352
  • Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007; 20: 270–6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.